STRATEGIC PARTNERING OPPORTUNITY

BioFutureRx | BFRx3711

Novel long-acting GLP-1 analog positioned for potential once-monthly SQ administration in obesity and type 2 diabetes

19%
Body-weight reduction in DIO mice
After 16 days of treatment

2.7x
Minipig half-life vs semaglutide
Company preclinical study

~420-450 hr
Projected human half-life
Approx. 18 days

May 2026

EXECUTIVE SNAPSHOT

BFRx3711 offers a differentiated GLP-1 profile anchored by potential once-monthly dosing

BFRx

Selected investment highlights

- Engineered GLP-1 analog designed to improve peptide stability, albumin binding and increased in vivo half-life.
- Preclinical package indicates semaglutide-like receptor activity with extended PK in rats and minipigs.
- Company is positioning BFRx3711 as a potential once-monthly subcutaneous (SQ) therapy for obesity and type 2 diabetes.
- BioFutureRx is seeking a strategic partner to support development toward a modeled Q1 2036 launch.

Intellectual property

Patent protection for BFRx-3711 molecule until 2045, with potential patent term extension up to 5 years. Patent details to be disclosed upon NDA.

Additional Patents may also be filed.

113 hr

Minipig half-life

Preclinical SQ study

~18 days

Projected human half-life

Approx. 420-450 hr

19%

Body-weight reduction

DIO mice after 16 days

4 days

Glucose <5 mmol/L

Vs. 2 days for semaglutide

Partnering ask

BioFuture Rx is asking for $10m in initial funding, pre-clinical studies and planning for phase 1.

The attached financial model allocates $170m of pre-launch investment to IND-enabling work, clinical development, NDA / scale-up and launch preparation through 2035.

Preclinical data indicate competitive efficacy with materially extended PK

Selected design features



Company-designed GLP-1 peptide modifications target improved DPP-4and other enzyme resistance, and stronger albumin binding.

Receptor activity

CRE-Luc / GLP1R / HEK293 results showed GLP-1R activation potency comparable to semaglutide, while Tag-Lite FRET assays demonstrated dose-dependent receptor binding both with and without 2% HSA.

PK / half-life

In rats, PK parameters were superior to semaglutide and tirzepatide. In minipigs, half-life was approximately 2.7x semaglutide, supporting the company's projected 420-450 hour human half-life.

Safety signal

BFRx3711 did not show GCGR receptor activation in cAMP testing, which management interprets as supportive of lower standalone hypoglycemia risk.

Anti-obesity efficacy

In DIO mouse studies, 28-day body-weight and food-consumption effects were similar to semaglutide, including 19% body-weight reduction by day 16.

Diabetes signal

Non-fasted glucose remained below 5 mmol/L for 4 days in DIO mice versus 2 days for semaglutide in the deck's comparative study.

COMPETITIVE POSITIONING

The asset targets whitespace between weekly market leaders and early monthly challengers

BFRx

Why this positioning matters

Weekly injectables currently dominate commercial GLP-1 economics. BFRx3711 is being developed to compete for the emerging convenience segment where less-frequent dosing may improve differentiation, compliance and strategic value.

Program	Status	Dosing ambition	Selected takeaway
BFRx3711	Preclinical / IND-track	Potential monthly SQ	Projected human half-life of ~420-450 hr with preclinical efficacy comparable to semaglutide in company studies
Semaglutide (Ozempic / Wegovy)	Commercial	Weekly SQ / daily oral	Established GLP-1 class benchmark in T2D and obesity
Tirzepatide (Mounjaro / Zepbound)	Commercial	Weekly SQ	Established dual-incretin benchmark with strong commercial momentum
MET-097i	Phase 2b	Monthly target	Selected monthly GLP-1 comparator referenced in company materials
MariTide	Phase 2	Monthly potential	Management notes high-dose formulation requirements may create injection-volume challenges

Management view: The company states that BFRx3711's shorter peptide profile (<40 amino acids) may support a simpler regulatory / manufacturing path relative to longer-peptide comparators.

BFRx

A defined roadmap creates multiple value inflection points through launch

Estimated Capital Plan

Stage	Estimated $M
Preclinical studies, CMC and IND approval	5.5
Clinical trials, Phase 1-3	135
CMC / Manufacturing / Validations to support Phase 2-3	25
Commercial license	4.5
Total	**170**

Lifecycle Options

Management believes BFRx3711 may ultimately have the same major indications being explored across the leading GLP-1 class.

Obesity | **T2D** | **NASH / MASH** | **Cardiovascular** | **CNS**

Illustrative expansion logic is informed by semaglutide / tirzepatide development precedent in company materials.

Company has the option to perform the phase 1, then license the drug to a big pharma for further clinical trials and marketing.

Illustrative economics show meaningful upside even under a more conservative operating case



Total GLP-1 TAM rises from $395bn in 2038 to $660bn in 2047 under the management market path.

Management Forecast

Total Market for GLP-1 T2D & Obesity Sales (2044): $660bn
Increasing from $395bn in 2035

Peak Share: 15.0%
10Y Revenue: $439.7bn
10Y Gross Profit: $175.9bn

Peak Sales: $99bn
Peak Gross Profit: $40bn

10 year CAGR of 54%
Expected Margin of 40%

First Launch in United States by end of 2034
Filing & Launch Strategy for Ex-US, especially Europe, AU, JP, China, India, etc. to be developed.

INVESTMENT THESIS

BioFutureRx is seeking a strategic partner to fund development and unlock class-wide optionality

BFRx

Takeaway

The opportunity combines differentiated dosing ambition, supportive preclinical data, a large commercial category and a visible clinical / regulatory roadmap.

1. Differentiated asset

Potential monthly GLP-1 profile supported by extended preclinical PK and efficacy signals that were benchmarked against semaglutide in company studies.

2. Attractive category

GLP-1 commercial value pools in obesity and T2D are large, durable and still expanding, with obesity representing the larger share of the modeled market.

3. Visible catalysts

IND, Phase 1, Phase 2, Phase 3, NDA and launch milestones create multiple value-inflection points on a defined path through 2036.

4. Platform optionality

BioFutureRx's peptide-design capabilities and the broader GLP-1 class precedent may support lifecycle expansion beyond the lead program over time.

Partnering objective

- Support IND-enabling work and clinical development of BFRx3711 in obesity and type 2 diabetes.
- Fund the modeled $170m pre-launch development program and capture value from the attached long-range commercial framework.
- Leverage BioFutureRx's peptide-design capabilities to pursue best-in-class positioning and broader lifecycle expansion.

Prepared from company materials and the attached forecast workbook. All projections and strategic claims should be independently diligenced.